Melanoma is deadly because it spreads to vital organs earlier and more aggressively than almost any other skin cancer. While it accounts for a small fraction of skin cancer diagnoses, it is responsible for a disproportionate share of skin cancer deaths. The difference comes down to biology: melanoma cells are uniquely equipped to migrate through the body, invade the brain, lungs, and liver, and resist the immune system’s attempts to stop them.
Melanoma Cells Are Built to Travel
Most skin cancers, like basal cell and squamous cell carcinomas, grow slowly and tend to stay put. Melanoma is fundamentally different. The cells it arises from, called melanocytes, originally developed during embryonic life from a group of cells known as the neural crest. These embryonic cells are natural travelers. They migrate long distances through the developing body to reach the skin, eyes, and other tissues.
When melanocytes become cancerous, they reactivate that ancient migration program. Research using chick embryo models has shown that metastatic melanoma cells switch on at least 12 genes associated with embryonic migration and tissue invasion that normal melanocytes keep turned off. Two-thirds of those reactivated genes are specifically involved in helping cells detach from their neighbors and move through tissue. In essence, melanoma doesn’t need to “learn” how to spread. It already has the genetic playbook and just needs to unlock it.
Two Growth Phases, One Critical Shift
The most common type of melanoma, superficial spreading melanoma, initially grows outward across the surface of the skin. This is called the radial growth phase. During this stage, the tumor stays thin and is highly curable. If caught here, five-year survival is effectively 100%.
The danger comes when the tumor shifts into the vertical growth phase, growing downward into deeper layers of skin. This transition happens when cancer cells lose normal cell cycle controls and begin forming a nodule in the dermis. Vertical-phase tumors grow roughly twice as fast as radial-phase tumors (about 0.13 mm per month versus 0.065 mm per month) and are significantly thicker at diagnosis. That thickness matters enormously: tumor depth, measured in millimeters, is the single most important predictor of whether melanoma will spread and kill.
Tumors thinner than 0.8 mm have less than a 5% chance of spreading to nearby lymph nodes. Once a tumor exceeds 1 mm, that risk climbs above 10%. Tumors thicker than 4 mm carry the worst prognosis. Some melanomas, called nodular melanomas, skip the radial phase entirely and start growing vertically from the beginning, which is why they’re often diagnosed at a more dangerous stage.
Where Melanoma Spreads
Once melanoma enters the vertical growth phase and reaches the lymphatic system or bloodstream, it can seed itself in distant organs with alarming efficiency. The lungs are typically the first major organ affected. Autopsy studies show that up to 85% of patients with late-stage melanoma have lung metastases, even when many of those were never detected during treatment.
The brain is another frequent target, and this is one of the reasons melanoma is so feared. Nearly half of advanced melanoma patients develop brain metastases during their lifetime, and autopsy studies put the true prevalence at 50 to 75%. Brain involvement is the direct cause of death in up to 54% of advanced cases. Historically, patients diagnosed with melanoma brain metastases survived a median of just four months, with only 10 to 20% alive at one year.
The liver is also heavily affected. Clinically, doctors detect liver spread in 10 to 20% of patients with metastatic melanoma, but autopsy data reveal that 54 to 77% actually had liver involvement. One striking example: melanoma originating in the eye metastasizes to the liver 87% of the time. Bone and intestine are other common sites. This widespread organ involvement is what separates melanoma from other skin cancers, which rarely spread beyond the skin at all.
The Survival Gap Between Early and Late Stages
The numbers tell a stark story. When melanoma is caught while still confined to the skin, the five-year survival rate is 100%. Once it reaches regional lymph nodes, survival drops to about 76%. If it has spread to distant organs, the five-year survival rate falls to roughly 35%. That dramatic drop, from near-certain survival to a one-in-three chance, reflects how quickly melanoma can overwhelm vital organs once it escapes the skin.
For context, about 332,000 people are diagnosed with melanoma globally each year, and nearly 59,000 die from it. Non-melanoma skin cancers are diagnosed at nearly four times that rate (about 1.2 million cases), yet their death toll is comparable at around 69,000. Melanoma kills a far higher percentage of the people it affects.
Genetic Mutations That Fuel Growth
About half of all melanomas carry a specific mutation in a gene called BRAF, most commonly the V600E variant. This mutation acts like a stuck accelerator, pushing cells to divide faster than they normally would. Tumors with this mutation can grow more quickly and become larger, which contributes to earlier spread and worse outcomes. The upside is that this mutation also provides a target for treatment: therapies designed to block the overactive BRAF protein can slow tumor growth, though not permanently.
How Melanoma Outmaneuvers Treatment
Even with modern immunotherapy, which has dramatically improved outcomes for many cancers, melanoma has multiple ways of evading destruction. Some tumors simply don’t display enough recognizable markers on their surface for immune cells to identify them as threats. Others disable the molecular signals that immune cells use to trigger cancer cell death. Some melanomas go further, actively recruiting immune-suppressing cells into their surroundings and physically blocking killer T cells from reaching the tumor.
These resistance mechanisms can be present from the start (primary resistance) or develop over time as the tumor adapts to treatment. This is why some patients respond dramatically to immunotherapy while others see little benefit, and why some patients who initially respond well eventually relapse. The ability to evolve around the immune system, whether natural or drug-enhanced, is a core reason melanoma remains lethal even in the era of advanced cancer treatment.
Why Thickness and Timing Matter So Much
The biology of melanoma creates a narrow window between a highly curable cancer and a potentially fatal one. A melanoma thinner than 1 mm is almost always survivable. A melanoma thicker than 4 mm has likely already sent microscopic seeds to distant organs. The difference between those two scenarios can be a matter of months.
Vertical-phase melanomas grow at roughly 0.13 mm per month on average, meaning a tumor could cross from low-risk to high-risk territory in well under a year. Diagnostic delays during the faster vertical growth phase can dramatically change outcomes. This is why melanoma surveillance focuses so heavily on identifying new or changing moles early: catching the tumor while it’s still in its radial phase, thin and surface-level, is the single most effective way to prevent it from becoming deadly.